Linking gene expression to tumor microenvironment using H&E features in stomach adenocarcinoma.

S S. Haditullah Bukhari (Shri Venkateshwara University, Meerut, UP, India) F Fazulur Vempalli (Canary Oncoceutics Inc, Phoenix, AZ) J J. David Warren (Canary Oncoceutics Inc, Phoenix, AZ) S Shyam Aggarwal (51Sir Ganga Ram Hospital, Delhi, India) A Aditya Sarin (SIR Ganga RAM Hospital, New Delhi, India) M Mandeep Singh Malhotra (CK Birla Hospital, New Delhi, India) R Rakesh K. Yadav (Shri Venkateshwara University, Meerut, UP, India) M Muzafar A. Macha A Ajaz Ahmad Bhat (Sidra Medicine, Doha, Qatar) H Harry Lander (Canary Oncoceutics Inc, Phoenix, AZ) T Tariq Masoodi (Canary Oncoceutics Inc, Phoenix, AZ)

Abstract

e14635 Background: Recent advances in computational pathology have revolutionized the analysis of histopathology images, enabling precise and rapid clinical outcome predictions. However, a significant challenge persists in translating computational insights into biologically meaningful data that informs clinical decisions. Human-interpretable image features (HIFs) have emerged as a solution, offering a detailed view of the tumor microenvironment (TME). In this study, we explored how HIFs derived from high-resolution histopathology images can predict the expression of genes associated with poor survival outcomes in stomach adenocarcinoma (STAD), aiming to bridge the gap between computational pathology and actionable clinical insights. Methods: Whole-slide histopathology images of STAD from The Cancer Genome Atlas were analyzed. Expert pathologists annotated labels were used to identify tissue types like cancer, stroma, necrosis, and normal tissue and cell types, including cancer cells, lymphocytes, macrophages, plasma cells, and fibroblasts. Using these annotations, convolutional neural networks were trained to classify these tissue and cell types, from which HIFs were extracted reflecting the biological composition of the TME, such as cell density ratios relative to surrounding tissues. We then identified genes with strong correlations to HIFs (ρ > 0.5) for further analysis. Results: Our results revealed high expression of four genes ABCA6, ABCA8, ADAM33, and ADAMTS10 that were significantly associated with poor survival outcomes in STAD (p < 0.01). Each gene demonstrated a strong correlation (ρ > 0.5 and p = < 0.01) with specific HIFs. ABCA6 and ABCA8 , genes involved in lipid transport, are linked to a high fibroblast-to-stroma density ratio. This stromal-dominant environment is a hallmark of therapy resistance and poor outcomes. ADAM33 and ADAMTS10 , proteases involved in extracellular matrix remodeling, were strongly correlated (ρ > 0.5a and p = < 0.01) with a high macrophage-to-stroma density ratio. This feature represents an immunosuppressive TME, often seen in aggressive and invasive cancers. Conclusions: These findings underscore the power of HIFs to reveal key TME characteristics. A stromal-dominant TME, defined by elevated ABCA6 and ABCA8 , and an immunosuppressive, macrophage-rich environment associated with increased ADAM33 and ADAMTS10 , serve as markers of disease aggressiveness and poor prognosis. By integrating these insights into AI-driven models, clinicians may identify high-risk patients earlier in their treatment journey, enabling personalized treatment strategies to improve outcomes for STAD patients.

Article Details

Volume / Issue Vol. 43, Issue 16_suppl
Published June 01, 2025
ISSN 0732-183X
Publisher Lippincott Williams & Wilkins

Journal Info

Journal of Clinical Oncology

Lippincott Williams & Wilkins

ISSN: 0732-183X Health Sciences

Authors (11)

S

S. Haditullah Bukhari

Shri Venkateshwara University, Meerut, UP, India

F

Fazulur Vempalli

Canary Oncoceutics Inc, Phoenix, AZ

J

J. David Warren

Canary Oncoceutics Inc, Phoenix, AZ

S

Shyam Aggarwal

51Sir Ganga Ram Hospital, Delhi, India

A

Aditya Sarin

SIR Ganga RAM Hospital, New Delhi, India

M

Mandeep Singh Malhotra

CK Birla Hospital, New Delhi, India

R

Rakesh K. Yadav

Shri Venkateshwara University, Meerut, UP, India

M

Muzafar A. Macha

A

Ajaz Ahmad Bhat

Sidra Medicine, Doha, Qatar

H

Harry Lander

Canary Oncoceutics Inc, Phoenix, AZ

T

Tariq Masoodi

Canary Oncoceutics Inc, Phoenix, AZ